Impact of immune checkpoint inhibitors on enfortumab vedotin cutaneous toxicity: A systematic clinicopathologic review
Authors:
- 28 May 2026
- journal article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 95 (3) , 885-888
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Enfortumab vedotin-related skin toxicities in patients with urothelial carcinoma: A systematic review and meta-analysisUrologic Oncology: Seminars and Original Investigations, 2025
- Histopathologic Comparison Among Drug Eruptions Induced by Enfortumab Vedotin, Brentuximab Vedotin, and TaxanesThe American Journal of Dermatopathology, 2024
- Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancerFrontiers in Oncology, 2024
- EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinomaAnnals of Oncology, 2023
- Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab VedotinThe Oncologist, 2022